Merus is interested in strategic collaborations with pharmaceutical companies with a strong background in therapeutic monoclonal antibodies and a strategic interest in the principal fields of application of OligoclonicsTM and Bispecifics- infectious diseases, oncology, and inflammatory diseases. For further inquiry, please contact T. Logtenberg, Chief Executive Officer:
T. Logtenberg. Ph.D
CEO, Merus BV
Padualaan 8
3584 CH Utrecht
The Netherlands
